Needham analyst Ami Fadia reiterated a Buy rating and $255.00 price target on Biogen (NASDAQ: BIIB).The analyst commented: "Biogen disclosed ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments